Piros

The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Piros

 

a lake in the Valdai Hills, on the border between Kalinin and Novgorod oblasts, RSFSR. It has an area of about 31.2 sq km and a maximum depth of 11.5 m. The lake is fed by mixed sources, chiefly snow. It freezes in late November or December and thaws in late April or May. The Berezaika River (Msta River basin) flows through Lake Piros, and a dam has been built where the Berezaika leaves the lake. The flow from Lake Piros is regulated to increase the flow and improve navigation on the Msta River.

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Cantor Fitzgerald analyst Elemer Piros notes that PolarityTE was granted a patent by the Canadian Intellectual Property Office related to methods for development and use of minimally polarized function cell micro-aggregate units.
Cantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating and $229 price target.
The interest towards those colour terms was incipient already at the end of the 19th century, when a medical scientist Istvan Csapodi published an article "Voros es piros" (1899).
(XAV900) SMALL CAP DRUG DEVELOPMENT COMPANIES: ELEMER PIROS - RODMAN & RENSHAW INC.
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Tocagen with a $28 price target after the company announced that the Phase 3 trial of Toca 511 and Toca FC in recurrent high-grade glioma will continue without modification.
(TAN901) INVESTMENT OPPORTUNITIES IN BIOTECHNOLOGY: ELEMER PIROS - RODMAN & RENSHAW INC.
Cantor Fitzgerald analyst Elemer Piros says PolarityTE's presentation yesterday highlighted differentiated case studies in which SkinTE was an effective treatment in restoring the regenerative properties of skin.
In a study highlighted by the International Wound Journal, PolarityTE's SkinTE was able to re-epithelialize the skin, which in turn led to complete healing and improvement in pain, of a patient with a greater than two year old large, chronic wound that failed numerous split-thickness skin grafts and treatments, Cantor Fitzgerald analyst Elemer Piros tells investors in a research note.
Cantor Fitzgerald analyst Elemer Piros raised his price target for uniQure (QURE) to $81 from $68 after Roche (RHHBY) acquired Spark Therapeutics (ONCE) for $4.8B.
Cantor Fitzgerald analyst Elemer Piros points out that in addition to its Q3 financial results today, Galmed Pharmaceuticals provided timelines for a Phase 3 initiation in mid-2019 and manufacturing of Phase 3 active pharmaceutical ingredients in Q4.
Apellis Pharmaceuticals last night reported that it initiated a temporary pause in dosing for its Phase 3 geographic atrophy program due to the occurrence of non-infectious inflammation associated potentially with a single lot of APL-2 drug, Cantor Fitzgerald analyst Elemer Piros tells investors in a research note.
Cantor Fitzgerald analyst Elemer Piros raised his price target for Corbus Pharmaceuticals to a Street-high $36 following abstracts from the American College of Rheumatology meeting, which is taking place in October.